Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a Liriodendron tulipifera L. bark extract for treating chronic myelogneous leukemia. More specifically, the present invention relates to the pharmaceutical composition, containing, as the active ingredient, the Liriodendron tulipifera L. bark extract useful in selectively inhibiting mutant enzyme T315I from a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, and to a use of epi-Tulipinolide which is an active ingredient of the composition.
Type:
Application
Filed:
April 23, 2014
Publication date:
March 24, 2016
Applicant:
CHO DANG PHARM. CO., LTD.
Inventors:
Ki Woon KIM, Hye Dong YOO, Soon Sun HONG, Soo Jung KIM, Hyun Seung LEE, Zhenghuan FANG, Su Jin KANG
Abstract: The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of Liriodendron tulipifera L., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a C1-C3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.
Type:
Application
Filed:
April 23, 2014
Publication date:
March 24, 2016
Applicant:
CHO DANG PHARM. CO., LTD.
Inventors:
Ki Woon KIM, Hye Dong YOO, Yong Hwan KIM, Il Kyong HWANG, Young Seon KIM, Mi Jung JU, Su Jin KANG
Abstract: The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.
Abstract: The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.
Abstract: The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera and, more specifically, to a dosage form for treating the gastrointestinal tract, the dosage form containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera.